Exited position

Ray Dalio’s Cme Group Inc (CME) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Bridgewater Associates, LPVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ3 2007Earliest verified positive filing snapshot
Latest statusExited positionBased on the latest supported relationship state
Peak shares410.77KHighest verified quarter-end share count
Quarters reported23Verified quarters with shares above zero
What happened?

Bridgewater Associates, LP first reported Cme Group Inc in Q3 2007. The reported position was increased and reduced across later filings. The latest verified relationship event shows that Bridgewater Associates, LP sold the entire position in Q1 2024, and the stock is no longer reported in the latest verified portfolio.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q1 2024
Sold the entire position−98.46K shares · No shares reported at quarter-end
Q4 2023
Bought 49.6% more+32.66K shares · 98.46K shares reported after the change
Filing context

Quarter-end price $210.60 · Estimated holding basis $208.28

Q3 2023
Sold 68.7% of the position−144.19K shares · 65.80K shares remained
Filing context

Quarter-end price $200.22 · Estimated holding basis $207.13

Q2 2023
Sold 30.5% of the position−92.06K shares · 209.99K shares remained
Filing context

Quarter-end price $185.29 · Estimated holding basis $207.13

Q1 2023
Sold 26.5% of the position−108.72K shares · 302.06K shares remained
Filing context

Quarter-end price $191.52 · Estimated holding basis $207.13

Q4 2022
Bought 29.1% more+92.51K shares · 410.77K shares reported after the change
Filing context

Quarter-end price $168.16 · Estimated holding basis $207.13

Portfolio importance

How important was Cme Group Inc in Bridgewater Associates, LP’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Last reported portfolio weight0.1%Q4 2023
Last reported rank#137of 742 reported positions
Peak portfolio weight0.4%Q4 2022
Best historical rank#56Q4 2022
At peak importanceQ4 2022
CME
0.4%
Largest holding
4.3%
Cross-investor discovery

Who else owns Cme Group Inc?

Also reported by 3 other tracked investors in their latest verified filings.

Seth KlarmanBaupost Group
CME2.5% of reported portfolio
Joel GreenblattGotham Asset Management
CME0.1% of reported portfolio
George SorosSoros Fund Management
CME0.1% of reported portfolio
Explore Cme Group Inc across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$276.012026-09-18

Market context only; not an investor transaction price.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

This tracker follows Bridgewater Associates, LP’s Form 13F disclosures, not Ray Dalio’s personal brokerage account. Form 13F reports quarter-end positions later and does not reveal exact trade dates or execution prices.